Sun Jiachun, Jiang Zhiyi, Shan Tanyou, Yang Ruina, Kong Dejiu, Rui Junshuai, Li Xinyang, Kong Guoqiang, Chang Baoping
Henan Key Laboratory of Cancer Epigenetics, Cancer Hospital, The First Affiliated Hospital, College of Clinical Medicine, Medical College of Henan University of Science and Technology, Luoyang, China.
Medical College, Henan University of Science and Technology, Luoyang, China.
Front Oncol. 2022 May 3;12:833486. doi: 10.3389/fonc.2022.833486. eCollection 2022.
Pulmonary sarcomatoid carcinoma (PSC) is a rare and aggressive subtype of non-small-cell lung cancer (NSCLC). Here, we present information on the clinicopathologic characteristics and clinical outcomes of this type of cancer. Clinicopathologic data from 55 patients treated at a single cancer center from January 2011 to December 2018 were retrospectively analyzed. The patients were mostly male (76.4%), with a median age of 66 years and a history of smoking (54.5%). Most had symptoms, and about 60% presented with locally advanced or metastatic disease at diagnosis. Of the 55 cases, 21 were diagnosed by surgical resection. Pleomorphic cancer was the most common subtype (58.1%). With a median follow-up period of 13.2 months, the average survival time of the patients was 16.1 months, and the median survival time was 12 months. The overall survival rates for 1, 2, and 3 years were 52.7%, 18.2%, and 9.1%, respectively. Univariate analysis showed that prognosis of the patients was influenced by tumor size, T stage, metastatic status, and surgery ( < 0.05). Multivariate analysis showed that T stage ( = 0.034) was an independent prognostic factor. There are few reports on the natural history of PSC, and its clinicopathological characteristics remain unclear. Herein, a retrospective review 55 individuals with PSC found that T stage was an independent predictor of survival. Surgical resection was associated with better prognosis.
肺肉瘤样癌（PSC）是一种罕见且侵袭性强的非小细胞肺癌（NSCLC）亚型。在此，我们呈现关于这类癌症的临床病理特征及临床结局的信息。对2011年1月至2018年12月在单个癌症中心接受治疗的55例患者的临床病理数据进行了回顾性分析。患者大多为男性（76.4%），中位年龄66岁，有吸烟史（54.5%）。大多数患者有症状，约60%在诊断时表现为局部晚期或转移性疾病。55例病例中，21例通过手术切除确诊。多形性癌是最常见的亚型（58.1%）。中位随访期为13.2个月，患者的平均生存时间为16.1个月，中位生存时间为12个月。1年、2年和3年的总生存率分别为52.7%、18.2%和9.1%。单因素分析显示，患者的预后受肿瘤大小、T分期、转移状态和手术的影响（<0.05）。多因素分析显示，T分期（=0.034）是独立的预后因素。关于PSC自然史的报道很少，其临床病理特征仍不清楚。在此，一项对55例PSC患者的回顾性研究发现，T分期是生存的独立预测因素。手术切除与较好的预后相关。
